JP2019521169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521169A5 JP2019521169A5 JP2019502689A JP2019502689A JP2019521169A5 JP 2019521169 A5 JP2019521169 A5 JP 2019521169A5 JP 2019502689 A JP2019502689 A JP 2019502689A JP 2019502689 A JP2019502689 A JP 2019502689A JP 2019521169 A5 JP2019521169 A5 JP 2019521169A5
- Authority
- JP
- Japan
- Prior art keywords
- kit
- antibody
- seq
- attenuated
- kit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002238 attenuated effect Effects 0.000 claims 14
- -1 GM2 Proteins 0.000 claims 9
- 229940122004 CD47 antagonist Drugs 0.000 claims 6
- 102220509128 Sphingosine 1-phosphate receptor 1_R120A_mutation Human genes 0.000 claims 6
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 5
- 102000014150 Interferons Human genes 0.000 claims 5
- 108010050904 Interferons Proteins 0.000 claims 5
- 102220522737 Mitogen-activated protein kinase kinase kinase 6_H57Y_mutation Human genes 0.000 claims 5
- 102220473689 Ras-related protein Rab-5A_Y89A_mutation Human genes 0.000 claims 5
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 229940079322 interferon Drugs 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102220535515 tRNA wybutosine-synthesizing protein 5_Y85A_mutation Human genes 0.000 claims 5
- 102220496408 Bone marrow stromal antigen 2_N65A_mutation Human genes 0.000 claims 4
- 102220496875 DNA dC->dU-editing enzyme APOBEC-3C_L80A_mutation Human genes 0.000 claims 4
- 102220555961 Ubiquitin-like modifier-activating enzyme 6_L117A_mutation Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102220482092 Nuclear cap-binding protein subunit 2_D114A_mutation Human genes 0.000 claims 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102220554170 APC membrane recruitment protein 1_L30A_mutation Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108010045374 CD36 Antigens Proteins 0.000 claims 2
- 101710204931 Ferroptosis suppressor protein 1 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 2
- 102000002227 Interferon Type I Human genes 0.000 claims 2
- 108010014726 Interferon Type I Proteins 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 102220498199 Negative regulator of P-body association_R33A_mutation Human genes 0.000 claims 2
- 102100023087 Protein S100-A4 Human genes 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 101150117918 Tacstd2 gene Proteins 0.000 claims 2
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102220554192 APC membrane recruitment protein 1_H34A_mutation Human genes 0.000 claims 1
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 1
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 1
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 claims 1
- 102100026293 Asialoglycoprotein receptor 2 Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102000049320 CD36 Human genes 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102220614548 Calmodulin-3_R23A_mutation Human genes 0.000 claims 1
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102220474004 Gamma-secretase subunit PEN-2_L26A_mutation Human genes 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000785944 Homo sapiens Asialoglycoprotein receptor 1 Proteins 0.000 claims 1
- 101000785948 Homo sapiens Asialoglycoprotein receptor 2 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 108010041012 Integrin alpha4 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims 1
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 108010077861 Kininogens Proteins 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 102220608646 Methyl-CpG-binding domain protein 1_R22K_mutation Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102220564303 Natural killer cells antigen CD94_Q40A_mutation Human genes 0.000 claims 1
- 102220564245 Natural killer cells antigen CD94_S25A_mutation Human genes 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100031574 Platelet glycoprotein 4 Human genes 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims 1
- 102220552456 Platelet-activating factor acetylhydrolase_K31A_mutation Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 102220599460 Protein NPAT_F27A_mutation Human genes 0.000 claims 1
- 102220599466 Protein NPAT_L15A_mutation Human genes 0.000 claims 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 101000600776 Rattus norvegicus Podoplanin Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 1
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 102200002501 c.98G>A Human genes 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102200044937 rs121913396 Human genes 0.000 claims 1
- 102220316641 rs146101365 Human genes 0.000 claims 1
- 102220157938 rs886063483 Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363982P | 2016-07-19 | 2016-07-19 | |
| US62/363,982 | 2016-07-19 | ||
| PCT/AU2017/000150 WO2018014067A1 (en) | 2016-07-19 | 2017-07-19 | Anti-cd47 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521169A JP2019521169A (ja) | 2019-07-25 |
| JP2019521169A5 true JP2019521169A5 (enExample) | 2020-08-20 |
| JP7241677B2 JP7241677B2 (ja) | 2023-03-17 |
Family
ID=60991761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502689A Active JP7241677B2 (ja) | 2016-07-19 | 2017-07-19 | 抗ｃｄ４７併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11618784B2 (enExample) |
| EP (1) | EP3487522A4 (enExample) |
| JP (1) | JP7241677B2 (enExample) |
| CN (2) | CN110087673A (enExample) |
| CA (1) | CA3030926A1 (enExample) |
| WO (1) | WO2018014067A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125637C2 (uk) * | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| US11779631B2 (en) | 2016-11-03 | 2023-10-10 | Pfizer Inc. | CD47 blockade therapy by HDAC inhibitors |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| TWI831759B (zh) | 2017-12-01 | 2024-02-11 | 美商思進公司 | Cd47抗體及其用於治療癌症之用途 |
| CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
| CN111303293B (zh) | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN112661855B (zh) * | 2019-10-16 | 2022-09-13 | 尚健单抗（北京）生物技术有限公司 | 含SIRPa变体的融合蛋白 |
| EP4069291A1 (en) | 2019-12-03 | 2022-10-12 | Evotec International GmbH | Interferon-associated antigen binding proteins and uses thereof |
| CN110981942B (zh) * | 2019-12-11 | 2022-07-08 | 中国药科大学 | 一种具有抗cd47免疫检查点拮抗活性的多肽rs-17及其应用 |
| WO2021139687A1 (zh) * | 2020-01-09 | 2021-07-15 | 信达生物制药(苏州)有限公司 | 抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用 |
| EP4168449A1 (en) * | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| US12338292B2 (en) * | 2020-09-18 | 2025-06-24 | IGI Therapeutics SA | CD47-CD38 bispecific antibodies |
| CN119584982A (zh) | 2022-05-18 | 2025-03-07 | 武田药品工业株式会社 | 抗cd38融合蛋白制剂 |
| CA3257502A1 (en) * | 2022-05-27 | 2023-11-30 | Takeda Pharmaceutical Company Limited | CD38 BINDING FUSION PROTEIN ASSAY |
| WO2024015586A1 (en) * | 2022-07-15 | 2024-01-18 | Whitehead Institute For Biomedical Research | Compositions and methods for treating cancer with interferon-omega and analogs thereof |
| CN118591566A (zh) * | 2022-11-07 | 2024-09-03 | 北京伟德杰生物科技有限公司 | 双功能融合蛋白及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5976531A (en) | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
| SK281143B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| ES2191702T3 (es) | 1994-03-17 | 2003-09-16 | Merck Patent Gmbh | Fv monocatenarios anti-egfr y anticuerpos anti-egfr. |
| ES2167391T3 (es) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| DE69638269D1 (de) | 1995-06-14 | 2010-11-18 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| WO1997042329A1 (en) | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6573067B1 (en) | 1998-01-29 | 2003-06-03 | Yale University | Nucleic acid encoding sodium channels in dorsal root ganglia |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| NZ512185A (en) | 1998-12-09 | 2004-02-27 | Dow Chemical Co | A method for manufacturing glycoproteins having human- type glycosylation in plant cells |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| AU6541801A (en) | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| AU2002315052A1 (en) | 2001-05-15 | 2002-11-25 | Emory University | Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47 |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| JP4562395B2 (ja) | 2002-01-09 | 2010-10-13 | メダレックス， インク． | Ｃｄ３０に対するヒトモノクローナル抗体 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| EP1594965A2 (en) | 2003-02-18 | 2005-11-16 | MERCK PATENT GmbH | Fusion proteins of interferon alpha muteins with improved properties |
| CA2545166A1 (en) | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| CA2578613A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| EP1799262A4 (en) | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| WO2007053718A1 (en) | 2005-10-31 | 2007-05-10 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| JP2009538273A (ja) | 2006-04-14 | 2009-11-05 | トルビオン ファーマシューティカルズ， インコーポレイテッド | 改造されたＦＣエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とＦｃ領域とを備える結合タンパク質 |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| US7854902B2 (en) | 2006-08-23 | 2010-12-21 | Nanotek, Llc | Modular and reconfigurable multi-stage high temperature microreactor cartridge apparatus and system for using same |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| TW200902554A (en) | 2007-05-08 | 2009-01-16 | Genentech Inc | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| PT2242512T (pt) | 2008-01-15 | 2016-07-18 | Univ Leland Stanford Junior | Métodos para manipular a fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP4311863A3 (en) | 2009-05-15 | 2024-04-10 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| EP4349868A3 (en) | 2010-05-14 | 2024-08-28 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| JP2014519338A (ja) * | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | 治療薬として使用される可溶性タンパク質 |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EA034778B1 (ru) | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Антитела к cd47 и способы их применения |
| WO2014009535A2 (en) | 2012-07-12 | 2014-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| RU2015122228A (ru) | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| HRP20192013T1 (hr) | 2012-12-17 | 2020-02-07 | Trillium Therapeutics Inc. | Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| WO2014144357A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| CA2909952C (en) * | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| AU2015204766B2 (en) * | 2014-01-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| ES2962260T3 (es) * | 2014-08-08 | 2024-03-18 | Univ Leland Stanford Junior | Proteínas de fusión SIRPa alfa-anticuerpo |
| UA125637C2 (uk) * | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| HK1257309A1 (zh) | 2015-09-21 | 2019-10-18 | Erasmus University Medical Center | 抗-cd47抗体及使用方法 |
-
2017
- 2017-07-19 US US16/317,077 patent/US11618784B2/en active Active
- 2017-07-19 CN CN201780055824.0A patent/CN110087673A/zh active Pending
- 2017-07-19 CN CN202311226685.7A patent/CN117717604A/zh active Pending
- 2017-07-19 CA CA3030926A patent/CA3030926A1/en active Pending
- 2017-07-19 EP EP17830099.2A patent/EP3487522A4/en not_active Withdrawn
- 2017-07-19 WO PCT/AU2017/000150 patent/WO2018014067A1/en not_active Ceased
- 2017-07-19 JP JP2019502689A patent/JP7241677B2/ja active Active
-
2022
- 2022-04-29 US US17/733,378 patent/US12258401B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534282A5 (enExample) | ||
| Nishimoto et al. | Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models | |
| JP7223822B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 | |
| Khan et al. | Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation | |
| JP7303314B2 (ja) | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 | |
| JP2024167225A (ja) | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 | |
| CN109071663B (zh) | 双特异性信号传导剂及其用途 | |
| US20210213063A1 (en) | Combination therapy with chimeric antigen receptor (car) therapies | |
| CN108350058B (zh) | Cd20疗法、cd22疗法和与cd19嵌合抗原受体(car)表达细胞的联合疗法 | |
| Sharron et al. | Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes | |
| IL260045A (en) | Polypeptide constructs and uses thereof | |
| JP2021525509A (ja) | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 | |
| EP3490590A2 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| JP2020528744A (ja) | がん細胞を標的化するキメラ抗原受容体のための方法および組成物 | |
| AU2015343079A1 (en) | Anti-CLDN chimeric antigen receptors and methods of use | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis | |
| CN111712517B (zh) | 靶向il-1rap的car-t细胞及它们的用途 | |
| CN114728178B (zh) | 靶向il-1rap的car-t细胞及它们在急性髓系白血病(aml)中的用途 | |
| Guo et al. | Humanized CD30-targeted chimeric antigen receptor t cells exhibit potent preclinical activity against Hodgkin’s lymphoma cells | |
| WO2021202801A1 (en) | Augmenting antigen-negative cell death in antigen-targeted immunotherapies | |
| TW201206472A (en) | IL-18 Receptor as a novel target of regulatory T cells in cancer | |
| Fournel et al. | CD4 mAbs PREVENT PROGRESSION OF ALLOACTIVATED CD4+ T CELLS INTO THE S PHASE OF THE CELL CYCLE WITHOUT INTERFERING WITH EARLY ACTIVATION SIGNALS1 | |
| Chiu | Natural Killer Cell Immune Engagers to Induce Optimal Anti-Tumor Activity | |
| Li et al. | YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma | |
| Huang et al. | Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer |